comput
search
chemic
librari
use
power
tool
rapid
discoveri
candid
compound
find
small
molecul
antifelin
infecti
periton
viru
fipv
properti
util
virtual
screen
techniqu
identifi
activ
site
viral
proteas
bind
avail
natur
compound
proteas
pro
play
import
role
replic
cycl
fipv
virus
within
famili
coronavirida
bestrank
candid
consensu
compound
base
three
dock
tool
evalu
assay
proteas
inhibitor
assay
recombin
fipv
pro
perform
screen
inhibitori
effect
candid
compound
ic
rang
determin
cellbas
assay
compound
show
better
ec
valu
broadspectrum
antivir
drug
ribavirin
proteas
inhibitor
lopinavir
test
condit
includ
previr
entri
postvir
entri
prophylact
activ
particularli
yield
best
select
index
rang
si
result
indic
natur
smallmolecular
compound
specif
target
pro
fipv
inhibit
replic
structur
modif
compound
may
gener
higher
antivir
potenc
develop
novel
therapi
fip
felin
infecti
periton
fip
caus
virul
biotyp
felin
coronaviru
fcov
genu
alphacoronaviru
famili
coronavirida
progress
fatal
diseas
cat
felin
infecti
periton
viru
fipv
mutat
form
parent
enter
form
fcov
call
felin
enter
coronaviru
fecv
fipv
infect
domest
cat
multipl
cat
household
worldwid
manasateinkij
et
al
pedersen
pedersen
fip
seriou
system
pyo
granulomat
diseas
caus
proteinrich
effus
bodi
caviti
diseas
progress
sever
within
week
month
cat
die
pedersen
sever
strategi
use
support
treatment
diseas
antiinflammatori
immunosuppress
drug
use
inhibit
inflammatori
process
reduc
clinic
sign
aim
expand
life
cat
combin
antivir
immunostimul
drug
appli
treatment
coronavirus
human
pedersen
howev
report
success
use
prevent
vaccin
antivir
therapi
treat
fip
genom
fipv
contain
positivesens
singlestrand
rna
approxim
nucleotid
length
open
read
frame
orf
encod
structur
nonstructur
accessori
gene
pedersen
pedersen
lin
et
al
twothird
fcov
genom
end
compris
two
overlap
orf
encod
two
polyprotein
translat
yield
polyprotein
lower
frequenc
ribosom
initi
translat
begin
undergo
frameshift
junction
result
long
polyprotein
http
receiv
septemb
receiv
revis
form
decemb
accept
decemb
pedersen
st
john
et
al
wang
et
al
similar
coronavirus
cov
fcov
contain
two
cystein
proteas
papainlik
proteas
pl
pro
proteas
pro
pro
also
known
main
proteas
pro
pedersen
st
john
et
al
wang
et
al
berri
et
al
play
pivot
role
viral
life
cycl
includ
process
polyprotein
viral
replic
polyprotein
subsequ
enzymat
cleav
nonstructur
function
protein
mainli
involv
proteolyt
process
viral
rna
synthesi
includ
replic
genom
synthesi
subgenom
mrna
remain
genom
contain
nine
orf
encod
four
structur
protein
spike
nucleocapsid
n
membran
envelop
e
protein
five
accessori
protein
pro
cov
similar
structur
function
properti
proteas
pro
picornaviru
noroviru
sarscov
kim
et
al
human
cov
pro
term
achil
heel
coronavirus
attract
target
drug
discoveri
pro
fipv
could
act
model
studi
potenti
antivir
drug
emerg
covassoci
diseas
vitro
assay
particularli
avail
fipv
system
inhibitor
target
pro
includ
pyridin
noxid
deriv
peptidomimet
analog
coval
inhibitor
peptidyl
compound
evalu
previous
balzarini
et
al
berri
et
al
natur
product
herbal
extract
could
repres
major
resourc
develop
antivir
drug
previou
studi
shown
natur
compound
exhibit
antivir
activ
pro
sarscov
interfer
viral
replic
lin
et
al
ryu
et
al
antivir
drug
target
pro
yet
avail
studi
util
silico
approach
search
candid
antifipv
lead
compound
avail
databas
particularli
natur
compound
target
fipv
pro
approach
could
circumv
major
invest
agent
drug
present
suitabl
properti
reduc
chanc
failur
downstream
vitro
vivo
assay
well
later
stage
clinic
test
addit
compound
identifi
method
may
provid
use
precursor
inform
develop
potenti
therapeut
agent
fip
emerg
covassoci
diseas
crystal
structur
pro
obtain
protein
data
bank
pdb
id
structur
process
prepar
molecular
dock
studi
prepar
involv
ad
hydrogen
atom
elimin
water
molecul
remov
ion
specifi
correct
proton
tautomer
state
bind
site
residu
calcul
partial
charg
use
program
chimera
ucsf
san
francisco
usa
prepar
structur
save
pdb
file
subsequ
molecular
dock
analysi
total
structur
file
natur
compound
retriev
pubchem
drugbank
zinc
nci
databas
gener
librari
initi
compound
screen
process
structur
compound
save
sdf
format
prior
dock
analysi
initi
virtual
screen
studi
carri
use
program
autodock
vina
trott
olson
built
pyrx
suit
version
evalu
empir
score
function
ligandprotein
complex
dallakyan
olson
input
file
convert
pdbqt
file
format
grid
paramet
grid
center
x
z
size
x
z
wherein
space
center
catalyt
pocket
fipv
pro
lamarckian
genet
algorithm
ga
set
default
paramet
includ
ga
run
individu
popul
gener
top
output
best
bind
affin
dock
run
store
studi
select
compound
rescor
use
differ
dock
algorithm
program
gold
version
licens
kindli
provid
assoc
prof
dr
kiattawe
choowongkomon
kasetsart
univers
base
ga
grid
paramet
interfac
region
similar
set
pyrx
ga
run
score
function
base
goldscor
fit
function
rank
bind
affin
second
program
rescor
icmpro
suit
version
use
calcul
energi
accord
mont
carlo
biasedprob
algorithm
grid
space
adjust
similarli
mention
softwar
paramet
receiv
oper
characterist
roc
curv
area
roc
curv
auc
appli
determin
perform
score
function
dock
perform
interact
proteinligand
complex
character
use
program
ligplot
version
laskowski
swindel
structur
complex
visual
use
ucsf
chimera
version
ucsf
san
francisco
usa
admet
absorpt
distribut
metabol
elimin
toxic
analysi
subsequ
perform
select
candid
compound
use
webbas
softwar
swissadm
daina
et
al
osiri
datawarrior
version
sander
et
al
gene
encod
pro
amplifi
cdna
fipv
strain
atcc
forward
primer
contain
ncoi
site
underlin
fxa
proteas
cleavag
site
ilegluglyarg
italic
revers
primer
contain
xhoi
site
underlin
pcr
product
digest
use
ncoi
xhoi
ligat
vector
recombin
proteas
plasmid
use
transform
e
coli
cell
streak
luriabertani
lb
agar
plate
contain
ampicillin
ampicillinresist
coloni
select
agar
plate
cultur
ml
lb
broth
contain
ampicillin
overnight
correct
construct
subsequ
transform
e
coli
protein
express
overnight
cultur
singl
transform
use
inocul
ml
fresh
lb
medium
contain
ampicillin
cell
grown
appropri
optic
densiti
od
induc
mm
thiogalactopyranosid
h
cell
harvest
centrifug
min
protein
purif
carri
describ
previous
briefli
gene
encod
fipv
pro
amplifi
use
pcr
insert
commerci
vector
express
enzym
thioredoxin
hexahi
tag
cleavag
site
fxa
proteas
nterminu
cleavag
tag
fxa
proteas
mixtur
load
onto
anoth
ninta
column
remov
thioredoxin
hexahi
tag
puriti
tagfre
fipv
pro
evalu
use
sdspage
protein
puriti
first
dialyz
buffer
contain
mm
trishcl
ph
mm
nacl
mm
edta
mm
mm
dithiothreitol
dtt
subject
next
experi
kinet
measur
fipv
pro
carri
follow
previous
describ
procedur
fipv
pro
ad
solut
contain
mm
bistri
ph
enhanc
fluoresc
result
cleavag
fluorogen
substrat
peptid
dabcylktsavlqsgfrkmeedan
fipv
pro
monitor
nm
dabcyl
excit
nm
edan
fluoresc
plate
reader
bmg
fluostar
optima
micropl
reader
ortenberg
germani
concentr
fipv
pro
use
measur
km
k
cat
valu
nm
substrat
concentr
rang
km
valu
initi
rate
substrat
consumpt
use
calcul
kinet
paramet
use
michaelismenten
equat
program
kaleidagraph
proteas
inhibit
assay
initi
rate
inhibit
nm
enzym
use
fluorogen
substrat
plot
differ
inhibitor
concentr
obtain
ic
valu
k
measur
perform
two
fix
inhibitor
concentr
ic
substrat
concentr
rang
reaction
mixtur
contain
nm
fipv
pro
lineweaverburk
plot
kinet
data
fit
use
nonlinear
regress
comput
program
kinetasyst
ii
intellikinet
state
colleg
pa
obtain
k
valu
competit
inhibitor
use
eq
equat
k
michaelismenten
constant
substrat
k
inhibit
constant
v
maxim
veloc
repres
inhibitor
substrat
concentr
reaction
mixtur
respect
crandellre
felin
kidney
crfk
cell
line
atcc
use
viral
propag
titrat
cell
line
maintain
modifi
eagl
medium
mem
carlsbad
usa
supplement
fetal
bovin
serum
fb
carlsbad
usa
mm
lglutamin
carlsbad
usa
antibioticantimycot
carlsbad
usa
crfk
cell
line
inocul
fipv
strain
atcc
incub
co
h
cytopath
effect
cpe
observ
invert
microscop
olympu
tokyo
japan
infect
cell
subject
doubl
freezethaw
cycl
releas
cellbound
virus
viru
suspens
clarifi
centrifug
min
clear
supernat
collect
kept
use
crfk
cell
seed
cellsml
onto
plate
incub
overnight
follow
day
cell
incub
vari
concentr
test
compound
h
three
independ
experi
perform
test
cytotox
determin
popul
live
cell
mt
solut
celltit
aqueou
nonradioact
cell
prolifer
assay
kit
madison
usa
ad
cultur
well
mt
tetrazolium
compound
bioreduc
metabol
activ
cell
formazan
product
turn
media
yellow
color
intens
proport
number
live
cell
incub
h
optic
densiti
sampl
measur
nm
use
multimod
reader
synergi
hybrid
multimod
reader
usa
absorb
valu
compound
treat
well
divid
averag
absorb
control
well
ratio
inhibit
calcul
cytotox
cytotox
concentr
cc
use
nonlinear
regress
analysi
result
present
mean
standard
deviat
use
statist
softwar
prism
version
graphpad
san
diego
usa
antivir
activ
candid
compound
examin
use
crfk
cell
infect
differ
concentr
fipv
two
biolog
three
technic
replic
crfk
cell
seed
cellsml
onto
plate
immunoperoxidas
monolay
assay
ipma
cellswel
plate
qpcrbase
detect
viru
inhibitori
activ
compound
test
concentr
compar
ribavirin
broadspectrum
antivir
drug
lopinavir
hivproteas
inhibitor
posit
control
drug
h
set
well
design
neg
control
consist
inhibitor
dmso
control
viru
control
inhibitor
viru
control
includ
experi
three
condit
gener
test
compound
determin
inhibitori
activ
compound
fipv
pro
entri
viru
host
cell
crfk
cell
incub
overnight
mention
fipv
strain
unit
tissu
cultur
infect
dose
tcid
inocul
simultan
differ
concentr
compound
separ
well
final
concentr
compound
per
well
base
cc
valu
obtain
cytotox
assay
cell
incub
h
order
determin
antivir
activ
candid
compound
intracellular
replic
fipv
crfk
cell
inocul
fipv
tcid
well
infect
cell
incub
h
viral
adsorpt
infectedcrfk
cell
incub
h
differ
concentr
compound
mention
order
determin
whether
small
molecul
could
enter
host
cell
demonstr
antivir
activ
fipv
infect
crfk
cell
incub
candid
compound
prior
viral
inocul
seed
crfk
cell
first
incub
overnight
follow
incub
differ
concentr
compound
h
compound
solut
remov
cell
wash
ringer
salin
solut
ph
cell
inocul
fipv
tcid
well
incub
h
ipma
perform
use
previous
describ
method
lekcharoensuk
et
al
briefli
infect
crfk
cell
fix
cold
methanol
room
temperatur
min
wash
pbst
buffer
primari
antibodi
detect
fipv
mous
monoclon
antibodi
specif
pancoronaviru
dilut
thermofish
carlsbad
usa
incub
infect
cell
h
treat
cell
wash
use
pbst
follow
incub
secondari
antibodi
goat
antimous
igghrp
antibodi
dilut
kirkegaard
perri
laboratori
madison
usa
h
antigenantibodi
reaction
stain
use
dab
substrat
dako
santa
clara
usa
observ
phasecontrast
invert
microscop
olympu
tokyo
japan
antivir
activ
test
compound
evalu
theerawatanasirikul
et
al
antivir
research
measur
intens
number
posit
fipvinfect
crfk
cell
use
ipma
assay
five
concentr
compound
ad
plate
duplic
imag
present
fipv
antigen
infect
cell
analyz
use
softwar
cellprofil
version
opensourc
code
avail
algorithm
broad
institut
freewar
avail
http
www
cellprofilerorgindexhtm
five
imag
concentr
test
compound
use
analysi
cellprofil
pipelin
util
project
modifi
opensourc
http
forumimagesc
pipelin
develop
calcul
intens
dabstain
cell
part
compar
unstain
cell
part
set
separ
clump
isol
cell
base
shape
three
antivir
condit
activ
compound
hit
compound
exhibit
least
inhibit
posit
fipvinfect
cell
without
compromis
cell
viabil
effect
concentr
compound
inhibit
infect
cell
ec
absenc
drug
determin
select
index
si
calcul
si
cc
ec
rna
extract
supernat
sampl
viral
rna
extract
use
trizol
total
rna
extract
kit
carlsbad
usa
accord
manufactur
instruct
rna
revers
transcrib
cdna
turn
templat
follow
realtim
quantit
polymeras
chain
reaction
qpcr
quantit
amplif
melt
curv
analysi
carri
realtim
qpcr
touch
thermal
cycler
biorad
usa
two
fipvspecif
primer
use
quantif
nucleic
acid
primer
fipvpcr
target
region
use
amplif
herrewegh
et
al
manasateinkij
et
al
sequenc
primer
specif
fcov
viral
genom
upstream
nucleotid
downstream
nucleotid
reaction
mixtur
qpcr
prepar
use
ssofast
evagreen
supermix
biorad
hercul
usa
cycl
condit
set
accord
manufactur
protocol
qpcr
amplif
sampl
carri
duplic
standard
curv
gener
tenfold
serial
dilut
plasmid
contain
fip
sequenc
linear
part
amplif
curv
plot
log
valu
start
concentr
yield
r
cq
valu
automat
gener
use
softwar
cfx
biorad
hercul
usa
absolut
quantiti
viral
copi
number
calcul
treatment
control
antivir
activ
select
candid
compound
present
percent
viral
reduct
compound
compar
control
valid
three
independ
experi
molecular
dock
analys
initi
carri
use
program
autodock
vina
redock
use
gold
icmpro
program
candid
compound
rank
accord
affinitybind
score
consensu
score
use
narrow
hit
supplementari
tabl
auc
valu
discrimin
sensit
specif
set
dock
result
individu
score
function
valid
dataset
consist
compound
suffici
analysi
result
show
significantli
higher
auc
three
rather
two
combin
score
function
fig
fifteen
select
compound
demonstr
strong
interact
fipv
pro
bind
pocket
suitabl
assay
recombin
histag
fipv
pro
express
e
coli
subsequ
purifi
ninta
column
follow
proteolyt
cleavag
fxa
proteas
tagfre
fipv
high
puriti
shown
sdspage
fig
sinc
extra
residu
hexahi
tag
cterminu
demonstr
interfer
dimer
sar
pro
hsu
et
al
tagfre
fipv
pro
prepar
studi
reflect
actual
activ
moreov
owe
high
degre
homolog
sar
pro
enzym
kinet
analysi
perform
use
fluorogen
substrat
dabcylktsavlqsgfrkmeedan
describ
previous
k
valu
fipv
pro
measur
k
cat
valu
fig
fifteen
compound
select
molecular
dock
analysi
subsequ
test
use
inhibit
assay
fipv
pro
primari
screen
seven
compound
show
inhibit
enzym
activ
concentr
tabl
seven
hit
display
ic
valu
respect
k
valu
seven
compound
fipv
pro
cid
indic
compound
competit
inhibitor
howev
compound
show
signific
inhibit
ic
valu
greater
ic
k
valu
test
compound
summar
supplementari
tabl
cytotox
assay
reveal
five
seven
hit
show
cytotox
cell
cytotox
cc
concentr
higher
cc
valu
compound
higher
ic
valu
supplementari
tabl
gener
ic
compound
less
cc
compound
effect
inhibit
viru
without
exhibit
signific
cell
toxic
evalu
viral
infect
base
differenti
express
fipv
antigen
within
cytoplasm
mockand
virusinfect
crfk
cell
antivir
activ
entri
viru
host
cell
determin
check
compound
could
inhibit
viru
stage
compound
demonstr
effect
inhibitori
activ
ribavirin
furthermor
compound
show
better
ec
valu
refer
proteas
inhibitor
lopinavir
compound
also
observ
inhibit
fipv
replic
crfk
cell
postvir
entri
step
fipv
infect
fipv
pro
also
express
viral
gene
result
indic
three
compound
better
ec
valu
prophylact
protect
activ
determin
check
compound
could
penetr
host
cell
still
possess
inhibitori
activ
prevent
fipv
infect
result
reveal
compound
could
complet
protect
cell
viru
infect
concentr
howev
remain
compound
could
inhibit
fipv
infect
condit
despit
good
ic
valu
compound
show
high
si
valu
three
condit
tabl
qpcr
result
show
percentag
viral
reduct
select
compound
three
condit
mostli
corrobor
ipma
result
fig
proteaseinhibit
antivir
activ
assay
demonstr
three
compound
possess
antifipv
activ
therefor
analyz
interact
compound
activ
site
pro
especi
key
amino
acid
residu
compound
firmli
place
within
bind
pocket
fipv
pro
catalyt
residu
present
bind
pocket
fipv
pro
exhibit
noncoval
interact
small
molecul
fig
favor
drug
design
noncoval
interact
amino
acid
residu
bind
pocket
fipv
pro
compound
detail
follow
compound
upper
panel
lower
panel
hydrophob
interact
hydrogen
bond
compound
b
upper
panel
lower
panel
b
hydrophob
interact
hydrogen
bond
compound
upper
panel
c
stack
hydrogen
bond
lower
panel
c
hydrophob
interact
fig
protein
purif
kinet
paramet
fipv
pro
sdspage
analysi
fipv
proteas
differ
stage
purif
procedur
lane
repres
molecular
mass
marker
lane
show
cell
lysat
without
iptg
induct
overexpress
fipv
proteas
fusion
tag
respect
lane
tag
proteas
ninta
column
chromatographi
lane
repres
purifi
fipv
pro
cleavag
fxa
remov
fusion
tag
two
extra
band
intact
fipv
pro
fusion
tag
lower
molecular
mass
appear
sdspage
lane
show
purifi
untag
proteas
arrow
pass
second
ninta
column
b
determin
kinet
paramet
fipv
proteas
initi
reaction
rate
proteas
differ
substrat
concentr
plot
substrat
concentr
obtain
v
max
k
valu
enzym
graphpad
prism
softwar
use
fit
kinet
data
use
michaelismenten
equat
k
cat
k
reaction
respect
hydrogen
bond
particular
compound
show
interact
thiol
group
cystein
imidazol
ring
histidin
fig
addit
evalu
druglik
physicochem
properti
candid
compound
use
lipinski
rule
five
lipinski
admet
properti
criteria
defin
four
rang
simpl
physicochem
paramet
molecular
weight
log
p
hbond
donor
hbond
acceptor
mostli
associ
oral
activ
drug
compound
abid
druglik
criteria
except
compound
show
less
potenti
orallyact
properti
supplementari
tabl
none
compound
possess
signific
mutagen
irrit
properti
studi
gener
recombin
pro
fipv
carri
nonredund
residu
nand
ctermini
first
report
describ
kinet
characterist
tagfre
fipv
pro
use
fluorogen
substrat
display
k
cat
km
respect
take
advantag
structurebas
virtual
screen
three
candid
compound
shown
possess
antivir
activ
compound
fungal
metabolit
call
chaetochromin
isol
fusarium
ascomycotina
hypocreal
penicillium
chaetomium
etc
chaetochromin
symmetr
dimer
two
group
ring
ugaki
et
al
chaetochromin
deriv
report
inhibitor
hiv
integras
base
strandtransf
assay
recombin
integras
ic
singh
et
al
use
silico
analysi
complex
chaetochromin
hra
protein
aidsassoci
cancer
simul
chaetochromin
b
observ
stabl
bind
pocket
make
promis
antivir
drug
omer
singh
studi
three
viral
infect
assay
show
chaetochromin
could
inhibit
fipv
infect
low
ic
ec
howev
might
cytotox
effect
host
cell
vivo
stictic
acid
extract
speci
lichen
usnea
articulata
lobaria
pulmonaria
xanthoparmelia
conspersa
xanthoparmelia
camtschadali
hypotrachyna
revoluta
white
et
al
stictic
acid
depsidon
produc
lichen
polyketid
uniqu
secondari
metabolit
contain
aromat
ring
commonli
found
stictic
acid
deriv
stictic
acid
could
reduc
product
reactiv
oxygen
speci
ro
cell
via
antioxid
activ
et
al
papadopoul
et
al
moreov
stictic
acid
could
react
within
cystein
triad
tumor
suppressor
protein
reduc
reactiv
human
cancer
wassman
et
al
note
pro
cov
also
contain
cystein
nucleophil
activ
site
catalyt
dyad
kim
et
al
dock
studi
compound
interact
hydrophob
bond
hydrophob
hydrogen
bond
also
observ
proteaseinhibitori
effect
supplementari
tabl
fipv
pro
inhibit
assay
stictic
acid
deriv
atranorin
extract
lichen
use
aceton
could
inhibit
replic
hepat
c
viru
vu
et
al
addit
stictic
acid
also
exhibit
integras
activ
ic
neamati
et
al
hitachimycin
natur
compound
first
isol
streptomyc
scabriporu
umezawa
et
al
also
known
stubomycin
one
acidcontain
macrocycl
lactam
polyketid
starter
unit
miyanaga
et
al
kudo
et
al
hitachimycin
relat
compound
vicenistatin
fluvirucin
fluvirucin
cremimycin
incednin
contain
aromat
ring
acid
polyketid
skeleton
hitachimycin
report
possess
antiprotozo
antitumor
properti
lack
literatur
antivir
effect
fluvirucin
core
macrocycl
lactam
similar
hitachimycin
show
antivir
effect
influenza
viru
type
victoria
strain
mdck
cell
cultur
ic
also
show
low
cc
valu
similar
observ
studi
narus
et
al
narus
et
al
antimicrobi
evid
indic
polyketid
synthas
could
synthes
metabolit
hitachimycin
fluvirucin
gene
analysi
cluster
studi
appli
identifi
biosynthet
gene
enzym
contribut
biosynthet
machineri
develop
new
compound
kudo
et
al
two
refer
inhibitor
ribavirin
lopinavir
includ
experi
ribavirin
synthet
nucleosid
ribosyl
purin
analog
antivir
activ
mechan
action
ribavirin
still
unclear
highli
variabl
among
patient
cameron
castro
zumla
et
al
howev
isol
known
interfer
synthesi
viral
mrna
viral
replic
primarili
indic
hepat
c
viru
dixit
perelson
activ
ribavirin
enhanc
use
combin
interferon
antivir
drug
synergist
inhibit
virus
rather
treatment
ribavirin
alon
report
merscov
sarscov
regimen
falzarano
et
al
omrani
et
al
ribavirin
combin
lopinavirritonavir
steroid
show
slight
reduct
mortal
rate
patient
infect
sarscov
chan
et
al
use
refer
antivir
compound
test
antivir
activ
candid
compound
sever
studi
preand
postvir
entri
experi
ribavirin
show
less
antivir
effect
fipv
compar
compound
ec
furthermor
show
antivir
effect
prophylaxi
studi
lopinavir
inhibitor
hiv
proteas
commonli
use
combin
ritonavir
treatment
hiv
boot
form
lopinavir
ritonavir
exhibit
antivir
activ
clinic
case
merscov
sarscov
chu
et
al
chan
et
al
expect
lopinavir
could
possibl
inhibit
pro
activ
howev
lopinavir
deriv
partial
inhibit
pro
sarscov
ic
valu
respect
wu
et
al
observ
lopinavir
effect
inhibit
fipv
stage
viral
entri
ec
possibl
lopinavir
may
higher
inhibitori
activ
toward
proteas
examin
cellbas
experi
papainlik
proteas
pro
common
proteas
cov
fingershap
subdomain
catalyt
triad
found
alphacov
includ
fipv
absent
betacov
lei
et
al
host
proteas
furin
proteas
action
lopinavir
might
involv
block
furinmedi
cleavag
viral
entri
therefor
mechan
interact
present
dash
line
bond
pink
dark
blue
stack
black
yellow
purpl
hydrogen
bond
green
hydrophob
interact
red
circl
ellips
ligandprotein
interact
visual
use
ucsf
chimera
version
ligplot
softwar
action
lopinavir
fipv
requir
investig
select
index
defin
ratio
cc
ec
use
determin
drug
select
cutoff
valu
si
hit
compound
set
studi
severson
et
al
studi
show
si
valu
previr
entri
assay
howev
postvir
entri
prophylact
antivir
activ
assay
show
si
valu
respect
bind
affin
compound
bind
pocket
fipv
pro
determin
kcalmol
use
program
autodock
vina
hand
si
valu
three
antivir
assay
therefor
promis
candid
natur
compound
drug
develop
inact
compound
also
inhibit
proteas
activ
could
control
fipv
infect
test
condit
possibl
antiproteas
activ
might
influenc
unknown
factor
within
cellcultur
condit
result
lower
activ
three
compound
ec
valu
better
broad
spectrum
antivir
drug
ribavirin
known
viral
proteas
inhibitor
lopinavir
less
effect
activ
examin
postvir
entri
prophylact
antivir
experi
tabl
case
postvir
entri
capabl
select
compound
penetr
plasma
membran
might
poor
therefor
intracellular
concentr
compound
less
actual
amount
ad
cultur
media
prophylact
purpos
compound
stabil
crucial
antivir
activ
compound
may
improv
util
special
drug
deliveri
system
direct
compound
macrophag
carri
insid
cell
recent
nanoparticleencapsul
drug
report
cargo
biopharmaceut
deliveri
target
cell
well
prevent
drug
degrad
review
visser
et
al
hand
modif
ad
function
group
carboxyl
methyl
acetyl
aldehyd
keton
compound
improv
bind
affin
solubl
stabil
howev
modif
decreas
druglik
characterist
studi
modifi
compound
ad
acetyl
group
shown
supplementari
tabl
strengthen
interact
pro
bind
pocket
might
enhanc
cell
permeabl
fipv
pro
contain
cy
residu
nucleophil
catalyt
dyad
st
john
et
al
wang
et
al
usual
inhibitor
pro
design
facilit
nucleophil
attack
proteas
carbonyl
residu
format
coval
bond
inhibitor
trap
enzymat
nucleophil
termin
catalyt
activ
function
group
commonli
term
warhead
base
carbonyl
group
contain
dipeptidyl
residu
differ
warhead
tiew
et
al
dipeptidyl
aldehyd
contain
carbonyl
group
nucleophil
donat
pair
electron
consequ
hydrolysi
key
catalyt
group
occur
activ
site
pro
studi
observ
candid
compound
contain
acyl
group
tend
share
lonepair
electron
activ
site
fipv
pro
accord
molecular
dock
analysi
three
best
candid
compound
interact
residu
bind
pocket
mainli
noncoval
bond
also
evalu
admet
properti
use
priorit
drug
modif
observ
pass
good
druglik
properti
small
molecul
refin
potenti
oral
drug
howev
violat
two
filter
nevertheless
modif
chemic
structur
abl
reduc
undesir
properti
increas
druglik
fragment
content
studi
fipv
pro
compound
complex
mainli
stabil
noncoval
interact
within
bind
pocket
therefor
besid
affin
molecul
protein
target
chemic
structur
especi
properti
relat
bioavail
serum
albumin
bind
consid
conclus
util
applic
computerbas
assay
virtual
screen
determin
potenti
antivir
candid
treatment
fip
target
fipv
pro
respons
polyprotein
process
cov
viral
replic
identifi
three
best
candid
compound
possess
characterist
antivir
inhibitor
natur
compound
show
strong
affin
toward
target
inhibit
fipv
infect
determin
molecular
dock
cellbas
assay
none
